FDA’s Nonproprietary Drug Naming Process Revamped To Match USP
Executive Summary
FDA’s Center for Drug Evaluation and Research has begun applying a new USP policy that generally requires the official drug product name to be expressed as the active moiety, not the pharmaceutical salt. The policy, which will not be applied retroactively, is aimed at bringing greater consistency to drug names.